RxDoctor Payments DataLook up a doctor →

Jai Varma, MD

Interventional Cardiology · Shreveport, LANPI 1952520488

Payments from drug & device makers

$185,851in general payments, 2019–2025

Across 599 payments — averaging $310.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scientia Vascular$173K
  • Novartis$2K
  • Abbott$1K
  • Johnson & Johnson$1K
  • AstraZeneca$830
  • Amgen$765
  • plus $7K from 40 others

What the payments were for

  • Speaking & faculty fees$2502%
  • Food & beverage$12,26497%
  • Education$1371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$185,851 in reported general payments places this provider in the 85th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$265,819
Medicare patients
929
Services billed
8,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban232$308,175
XareltoRivaroxaban78$99,185
EntrestoSacubitril/Valsartan62$77,258
Repatha SureclickEvolocumab80$65,791
JardianceEmpagliflozin14$18,401
FarxigaDapagliflozin Propanediol17$14,606
Metoprolol Succinate314$5,347
Atorvastatin Calcium541$4,850
Nebivolol Hcl46$4,033
Rosuvastatin Calcium256$3,932
ClopidogrelClopidogrel Bisulfate319$3,883
Droxidopa12$3,689
Bisoprolol Fumarate138$3,663
Ezetimibe103$3,057
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid39$3,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$483$308,175232 claims
Johnson & JohnsonXarelto$1,148$99,18578 claims
NovartisEntresto$1,754$77,25862 claims
Boehringer IngelheimJardiance$375$18,40114 claims
AstraZenecaFarxiga$830$14,60617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →